GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

mufemilast   Click here for help

GtoPdb Ligand ID: 14395

Synonyms: Hemay005 | Momishin® (China)
Approved drug Immunopharmacology Ligand
mufemilast is an approved drug
Compound class: Synthetic organic
Comment: Mufemilast (Hemay005) is a PDE4 inhibitor with anti-inflammatory activity [1,3].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 9
Hydrogen bond donors 1
Rotatable bonds 9
Topological polar surface area 152.76
Molecular weight 466.53
XLogP 0.66
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES CCOC1=CC(=CC=C1OC)[C@@H](CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C
Isomeric SMILES CCOC1=C(C=CC(=C1)[C@@H](CS(=O)(=O)C)N2C(=O)C3=CSC(=C3C2=O)NC(=O)C)OC
InChI InChI=1S/C20H22N2O7S2/c1-5-29-16-8-12(6-7-15(16)28-3)14(10-31(4,26)27)22-19(24)13-9-30-18(21-11(2)23)17(13)20(22)25/h6-9,14H,5,10H2,1-4H3,(H,21,23)/t14-/m1/s1
InChI Key PRSNGWLHNWGOKD-CQSZACIVSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
Mufemilast (Hemay005) was advanced as an immunomodulatory clinical lead for a broad-spectrum of chronic inflammatory diseases. The FDA granted orphan drug designation for Behcet`s syndrome. First approval was granted by China's NMPA in 2025, to treat moderate to severe plaque psoriasis [2].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04839328 A Phase Ⅲ Efficacy and Safety Study of Hemay005 in Subjects With Moderate to Severe Plaque Psoriasis Phase 3 Interventional Ganzhou Hemay Pharmaceutical Co., Ltd
NCT07314242 A Study to Investigate the Biomarkers of Hemay005 in Adult Participants With Moderate to Severe COPD Phase 2 Interventional Ganzhou Hemay Pharmaceutical Co., Ltd
NCT06145893 A Study of Efficacy and Safety of Hemay005 Tablets in Patients With Behçet's Disease Phase 3 Interventional Ganzhou Hemay Pharmaceutical Co., Ltd
NCT03007810 Safety and Pharmacokinetics of Hemay005 In Healthy Male Subjects Phase 1 Interventional Tianjin Hemay Bio-Tech Co., Ltd 3